Brolucizumab outperforms aflibercept in fluid resolution
- Posted on: Jun 10 2019
- Leave a response
Findings from a pair of phase 3 trials suggest that the new VEGF inhibitor brolucizumab is more effective than aflibercept at resolving retinal fluid in patients with wet AMD.
Source: AAO
Posted in: Uncategorized
